Magle Chemoswed (MAGLE) Q3 2025 earnings summary

Executive summary

• Q3 2025 saw a rebound with improved operational performance, higher EBITDA, and progress in integrating recent acquisitions, despite ongoing market headwinds and restructuring costs.

• Strong performance from Chemoswed and Biopolymers offset continued weakness in Biopharma, while Pharmacept achieved regulatory milestones and expanded market reach.

Financial highlights

• Q3 2025 revenue was 78.3 MSEK, down from 81.6 MSEK in Q3 2024; EBITDA rose to 33.4 MSEK from 26.5 MSEK.

• Operating profit (EBIT) for Q3 2025 was 20.3 MSEK, up from 13.8 MSEK; profit after tax was 3.1 MSEK, down from 9.6 MSEK.

• For Jan–Sep 2025, revenue increased to 218.6 MSEK (172.1 MSEK in 2024), but EBITDA fell to 31.6 MSEK (38.8 MSEK), and EBIT was -6.6 MSEK (19.2 MSEK).

• Profit after tax for Jan–Sep 2025 was -25.8 MSEK, compared to 12.7 MSEK in the prior year.

• Cash flow from operating activities for Jan–Sep 2025 was -48.9 MSEK, compared to 11.6 MSEK in 2024.

Outlook and guidance

• 2025 is positioned as a critical year for restructuring and integration, with focus on systems alignment, operational synergies, and building a scalable foundation.

• Management expects one-time costs and complexity but anticipates a resilient, margin-consistent, and integrated platform for future growth.